Journal of Surgical Research
Volume 152, Issue 1 , Pages 18-25 , March 2009

ERK/BCL-2 Pathway in the Resistance of Pancreatic Cancer to Anoikis

Received 9 April 2007

References 

  1. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 1994;124:619
  2. Grossmann J. Molecular mechanisms of “detachment-induced apoptosis—Anoikis”. Apoptosis. 2002;7:247
  3. Liotta LA, Kohn E. Anoikis: Cancer and the homeless cell. Nature. 2004;430:973
  4. Lillemoe KD, Yeo CJ, Cameron JL. Pancreatic cancer: State-of-the-art care. CA Cancer J Clin. 2000;50:241
  5. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol. 2001;13:555
  6. Bold RJ, Hess KR, Pearson AS, et al. Prognostic factors in resectable pancreatic cancer: p53 and BCL-2. J Gastrointest Surg. 1999;3:263
  7. Sun CY, Wang BL, Hu CQ, et al. Expression of the bcl-2 gene and its significance in human pancreatic carcinoma. Hepatobiliary Pancreat Dis Int. 2002;1:306
  8. Campani D, Esposito I, Boggi U, et al. Bcl-2 expression in pancreas development and pancreatic cancer progression. J Pathol. 2001;194:444
  9. Bold RJ, Chandra J, McConkey DJ. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol. 1999;6:279
  10. Bold RJ, Virudachalam S, McConkey DJ. BCL2 expression correlates with metastatic potential in pancreatic cancer cell lines. Cancer. 2001;92:1122
  11. Boucher MJ, Morisset J, Vachon PH, et al. MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem. 2000;79:355
  12. Chadha KS, Khoury T, Yu J, et al. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol. 2006;13:933
  13. Alessi DR, Cuenda A, Cohen P, et al. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase in vitro and in vivo. J Biol Chem. 1995;270:27489
  14. Bretland AJ, Lawry J, Sharrard RM. A study of death by anoikis in cultured epithelial cells. Cell Prolif. 2001;34:199
  15. Fahy BN, Schlieman MG, Virudachalam S, et al. Schedule-dependent molecular effects of the proteasome inhibitor Velcade and gemcitabine in pancreatic cancer. J Surg Res. 2003;113:88
  16. Fahy BN, Schlieman MG, Virudachalam S, et al. AKT inhibition is associated with chemosensitization in the pancreatic cancer cell line MIA-PaCa-2. Br J Cancer. 2003;89:391
  17. Douziech N, Calvo E, Laine J, et al. Activation of MAP kinases in growth responsive pancreatic cancer cell line. Cellular Signalling. 1999;11:591
  18. Yoon S, Seger R. The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions. Growth Factors. 2006;24:21
  19. Eckert LB, Repasky GA, Ulku AS, et al. Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. Cancer Res. 2004;64:4585
  20. Wei L, Yang Y, Zhang X, et al. Altered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis. Oncogene. 2004;23:9052
  21. Rul W, Zugasti O, Roux P, et al. Activation of ERK, controlled by Rac1 and Cdc42 via Akt, is required for anoikis. Ann NY Acad Sci. 2002;973:145
  22. Chang GC, Hsu SL, Tsai JR, et al. Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol. 2004;502:169
  23. Fahy BN, Schlieman MG, Mortenson MM, et al. Targeting BCL-2 overexpression in various human malignancies through NF-B inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol. 2005;56:46
  24. Zhao Y, Shen S, Guo J, et al. Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells. J Surg Res. 2006;136:325
  25. Cohen SJ, Ho L, Ranganathan S, et al. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol. 2003;21:1301
  26. Tolcher AW, Kuhn J, Schwartz G, et al. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2004;10:5048
  27. Bedikian AY, Millward M, Pehamberger H, et al. Oblimersen Melanoma Study Group Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group. J Clin Oncol. 2006;24:4738
  28. Tahir SK, Yang X, Anderson MG, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res. 2007;67:1176

PII: S0022-4804(08)00364-8

doi: 10.1016/j.jss.2008.05.017

Journal of Surgical Research
Volume 152, Issue 1 , Pages 18-25 , March 2009

Article Tools

* Image Usage & Resolution